

Shaomeng Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6598285/publications.pdf>

Version: 2024-02-01

511
papers

31,997
citations

3874

91
h-index

6872

160
g-index

529
all docs

529
docs citations

529
times ranked

34735
citing authors

#	ARTICLE	IF	CITATIONS
1	Mcl-1 levels critically impact the sensitivities of human colorectal cancer cells to APG-1252-M1, a novel Bcl-2/Bcl-XL dual inhibitor that induces Bax-dependent apoptosis. <i>Neoplasia</i> , 2022, 29, 100798.	2.3	5
2	Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1. <i>Cancer Gene Therapy</i> , 2022, 29, 1558-1569.	2.2	7
3	The novel BET degrader, QCA570, is highly active against the growth of human NSCLC cells and synergizes with osimertinib in suppressing osimertinib-resistant EGFR-mutant NSCLC cells.. <i>American Journal of Cancer Research</i> , 2022, 12, 779-792.	1.4	0
4	Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models. <i>BMC Cancer</i> , 2022, 22, .	1.1	13
5	Therapeutic Strategies to Target the Androgen Receptor. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 8772-8797.	2.9	18
6	Potency and Selectivity Optimization of Tryptophanolâ€Derived Oxazoloisoindolinones: Novel p53 Activators in Human Colorectal Cancer. <i>ChemMedChem</i> , 2021, 16, 250-258.	1.6	6
7	Confronting Racism in Chemistry Journals. <i>ACS ES&T Engineering</i> , 2021, 1, 3-5.	3.7	0
8	Targeting transcriptional regulation of SARS-CoV-2 entry factors <i>ACE2</i> and <i>TMPRSS2</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	142
9	Confronting Racism in Chemistry Journals. <i>ACS ES&T Water</i> , 2021, 1, 3-5.	2.3	0
10	Follicular Lymphomaâ€associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation. <i>Clinical Cancer Research</i> , 2021, 27, 2301-2313.	3.2	16
11	The ubiquitin ligase MDM2 sustains STAT5 stability to control T cell-mediated antitumor immunity. <i>Nature Immunology</i> , 2021, 22, 460-470.	7.0	50
12	Topography of transcriptionally active chromatin in glioblastoma. <i>Science Advances</i> , 2021, 7, .	4.7	19
13	SD-91 as A Potent and Selective STAT3 Degradable Capable of Achieving Complete and Long-Lasting Tumor Regression. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 996-1004.	1.3	21
14	Selective inhibition of cullin 3 neddylation through covalent targeting DCN1 protects mice from acetaminophen-induced liver toxicity. <i>Nature Communications</i> , 2021, 12, 2621.	5.8	15
15	Discovery of M-1121 as an Orally Active Covalent Inhibitor of Menin-MLL Interaction Capable of Achieving Complete and Long-Lasting Tumor Regression. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 10333-10349.	2.9	13
16	Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degradable of Androgen Receptor for the Treatment of Prostate Cancer. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 12831-12854.	2.9	69
17	Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degradable of Androgen Receptor for the Treatment of Advanced Prostate Cancer. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 13487-13509.	2.9	78
18	Discovery of New 4-Indolyl Quinazoline Derivatives as Highly Potent and Orally Bioavailable P-Glycoprotein Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 14895-14911.	2.9	27

#	ARTICLE	IF	CITATIONS
19	Discovery of EEDi-5273 as an Exceptionally Potent and Orally Efficacious EED Inhibitor Capable of Achieving Complete and Persistent Tumor Regression. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 14540-14556.	2.9	14
20	BET protein degradation triggers DR5-mediated immunogenic cell death to suppress colorectal cancer and potentiate immune checkpoint blockade. <i>Oncogene</i> , 2021, 40, 6566-6578.	2.6	14
21	Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment. <i>Neoplasia</i> , 2020, 22, 111-119.	2.3	101
22	A highly potent PROTAC androgen receptor (AR) degrader ARD-61 effectively inhibits AR-positive breast cancer cell growth in vitro and tumor growth in vivo. <i>Neoplasia</i> , 2020, 22, 522-532.	2.3	44
23	Epigenetics 2.0: Special Issue on Epigeneticsâ€™ Call for Papers. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 12129-12130.	2.9	1
24	Confronting Racism in Chemistry Journals. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 559-561.	2.5	0
25	Confronting Racism in Chemistry Journals. <i>Biochemistry</i> , 2020, 59, 2313-2315.	1.2	0
26	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. <i>ACS Biomaterials Science and Engineering</i> , 2020, 6, 2707-2708.	2.6	0
27	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. <i>ACS Central Science</i> , 2020, 6, 589-590.	5.3	0
28	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. <i>ACS Chemical Biology</i> , 2020, 15, 1282-1283.	1.6	0
29	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. <i>ACS Chemical Neuroscience</i> , 2020, 11, 1196-1197.	1.7	0
30	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. <i>ACS Earth and Space Chemistry</i> , 2020, 4, 672-673.	1.2	0
31	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. <i>ACS Energy Letters</i> , 2020, 5, 1610-1611.	8.8	1
32	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. <i>ACS Macro Letters</i> , 2020, 9, 666-667.	2.3	0
33	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. , 2020, 2, 563-564.		0
34	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. <i>ACS Nano</i> , 2020, 14, 5151-5152.	7.3	2
35	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. <i>ACS Photonics</i> , 2020, 7, 1080-1081.	3.2	0
36	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 455-456.	2.5	0

#	ARTICLE	IF	CITATIONS
37	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. ACS Sustainable Chemistry and Engineering, 2020, 8, 6574-6575.	3.2	0
38	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Analytical Chemistry, 2020, 92, 6187-6188.	3.2	0
39	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Chemistry of Materials, 2020, 32, 3678-3679.	3.2	0
40	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Environmental Science and Technology Letters, 2020, 7, 280-281.	3.9	1
41	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Journal of Chemical Education, 2020, 97, 1217-1218.	1.1	1
42	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Journal of Proteome Research, 2020, 19, 1883-1884.	1.8	0
43	Confronting Racism in Chemistry Journals. Langmuir, 2020, 36, 7155-7157.	1.6	0
44	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. ACS Applied Polymer Materials, 2020, 2, 1739-1740.	2.0	0
45	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. ACS Combinatorial Science, 2020, 22, 223-224.	3.8	0
46	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. ACS Medicinal Chemistry Letters, 2020, 11, 1060-1061.	1.3	0
47	Selectively Targeting Tropomyosin Receptor Kinase A (TRKA) via PROTACs. Journal of Medicinal Chemistry, 2020, 63, 14560-14561.	2.9	5
48	Editorial Confronting Racism in Chemistry Journals. , 2020, 2, 829-831.		0
49	Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression. Journal of Medicinal Chemistry, 2020, 63, 13994-14016.	2.9	11
50	Confronting Racism in Chemistry Journals. Journal of Physical Chemistry Letters, 2020, 11, 5279-5281.	2.1	1
51	Confronting Racism in Chemistry Journals. ACS Applied Energy Materials, 2020, 3, 6016-6018.	2.5	0
52	Confronting Racism in Chemistry Journals. ACS Central Science, 2020, 6, 1012-1014.	5.3	1
53	Confronting Racism in Chemistry Journals. Industrial & Engineering Chemistry Research, 2020, 59, 11915-11917.	1.8	0
54	Confronting Racism in Chemistry Journals. Journal of Natural Products, 2020, 83, 2057-2059.	1.5	0

#	ARTICLE	IF	CITATIONS
55	Confronting Racism in Chemistry Journals. ACS Medicinal Chemistry Letters, 2020, 11, 1354-1356.	1.3	0
56	Confronting Racism in Chemistry Journals. Journal of the American Society for Mass Spectrometry, 2020, 31, 1321-1323.	1.2	1
57	Excellence in Medicinal Chemistry Research from Japan. Journal of Medicinal Chemistry, 2020, 63, 8877-8879.	2.9	0
58	Confronting Racism in Chemistry Journals. Energy & Fuels, 2020, 34, 7771-7773.	2.5	0
59	Confronting Racism in Chemistry Journals. ACS Sensors, 2020, 5, 1858-1860.	4.0	0
60	Confronting Racism in Chemistry Journals. ACS Nano, 2020, 14, 7675-7677.	7.3	2
61	The 2020 Nobel Prize in Physiology or Medicine. Journal of Medicinal Chemistry, 2020, 63, 13197-13204.	2.9	5
62	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Biochemistry, 2020, 59, 1641-1642.	1.2	0
63	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Journal of Chemical & Engineering Data, 2020, 65, 2253-2254.	1.0	0
64	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Organic Process Research and Development, 2020, 24, 872-873.	1.3	0
65	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. ACS Omega, 2020, 5, 9624-9625.	1.6	0
66	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. ACS Applied Electronic Materials, 2020, 2, 1184-1185.	2.0	0
67	Introduction: Drug Metabolism and Toxicology Special Issue. Journal of Medicinal Chemistry, 2020, 63, 6249-6250.	2.9	2
68	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. ACS Applied Materials & Interfaces, 2020, 12, 20147-20148.	4.0	5
69	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Journal of Physical Chemistry C, 2020, 124, 9629-9630.	1.5	0
70	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Journal of Physical Chemistry Letters, 2020, 11, 3571-3572.	2.1	0
71	Discovery of Potent Small-Molecule Inhibitors of MLL Methyltransferase. ACS Medicinal Chemistry Letters, 2020, 11, 1348-1352.	1.3	9
72	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. ACS Synthetic Biology, 2020, 9, 979-980.	1.9	0

#	ARTICLE	IF	CITATIONS
73	Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degradator of SHP2 Protein. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 7510-7528.	2.9	89
74	Update to Our Reader, Reviewer, and Author Communities"April 2020. <i>ACS Applied Energy Materials</i> , 2020, 3, 4091-4092.	2.5	0
75	Confronting Racism in Chemistry Journals. <i>Journal of Chemical Theory and Computation</i> , 2020, 16, 4003-4005.	2.3	0
76	Confronting Racism in Chemistry Journals. <i>Journal of Organic Chemistry</i> , 2020, 85, 8297-8299.	1.7	0
77	Confronting Racism in Chemistry Journals. <i>Analytical Chemistry</i> , 2020, 92, 8625-8627.	3.2	0
78	Confronting Racism in Chemistry Journals. <i>Journal of Chemical Education</i> , 2020, 97, 1695-1697.	1.1	0
79	Confronting Racism in Chemistry Journals. <i>Organic Process Research and Development</i> , 2020, 24, 1215-1217.	1.3	0
80	Confronting Racism in Chemistry Journals. <i>ACS Sustainable Chemistry and Engineering</i> , 2020, 8, .	3.2	0
81	Confronting Racism in Chemistry Journals. <i>Chemistry of Materials</i> , 2020, 32, 5369-5371.	3.2	0
82	Confronting Racism in Chemistry Journals. <i>Chemical Research in Toxicology</i> , 2020, 33, 1511-1513.	1.7	0
83	Confronting Racism in Chemistry Journals. <i>Inorganic Chemistry</i> , 2020, 59, 8639-8641.	1.9	0
84	EEDi-5285: An Exceptionally Potent, Efficacious, and Orally Active Small-Molecule Inhibitor of Embryonic Ectoderm Development. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 7252-7267.	2.9	22
85	Confronting Racism in Chemistry Journals. <i>ACS Applied Nano Materials</i> , 2020, 3, 6131-6133.	2.4	0
86	Confronting Racism in Chemistry Journals. <i>ACS Applied Polymer Materials</i> , 2020, 2, 2496-2498.	2.0	0
87	Confronting Racism in Chemistry Journals. <i>ACS Chemical Biology</i> , 2020, 15, 1719-1721.	1.6	0
88	Update to Our Reader, Reviewer, and Author Communities"April 2020. <i>Journal of Chemical Theory and Computation</i> , 2020, 16, 2881-2882.	2.3	0
89	Confronting Racism in Chemistry Journals. <i>Organic Letters</i> , 2020, 22, 4919-4921.	2.4	4
90	Confronting Racism in Chemistry Journals. <i>ACS Applied Materials & Interfaces</i> , 2020, 12, 28925-28927.	4.0	13

#	ARTICLE	IF	CITATIONS
91	Confronting Racism in Chemistry Journals. <i>Crystal Growth and Design</i> , 2020, 20, 4201-4203.	1.4	1
92	Confronting Racism in Chemistry Journals. <i>Chemical Reviews</i> , 2020, 120, 5795-5797.	23.0	2
93	Confronting Racism in Chemistry Journals. <i>ACS Catalysis</i> , 2020, 10, 7307-7309.	5.5	1
94	Confronting Racism in Chemistry Journals. <i>Biomacromolecules</i> , 2020, 21, 2543-2545.	2.6	0
95	Confronting Racism in Chemistry Journals. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 6575-6577.	2.9	0
96	Confronting Racism in Chemistry Journals. <i>Macromolecules</i> , 2020, 53, 5015-5017.	2.2	0
97	Confronting Racism in Chemistry Journals. <i>Nano Letters</i> , 2020, 20, 4715-4717.	4.5	5
98	Confronting Racism in Chemistry Journals. <i>Organometallics</i> , 2020, 39, 2331-2333.	1.1	0
99	Confronting Racism in Chemistry Journals. <i>Journal of the American Chemical Society</i> , 2020, 142, 11319-11321.	6.6	1
100	BRD4 Levels Determine the Response of Human Lung Cancer Cells to BET Degradors That Potently Induce Apoptosis through Suppression of Mcl-1. <i>Cancer Research</i> , 2020, 80, 2380-2393.	0.4	28
101	Confronting Racism in Chemistry Journals. <i>Accounts of Chemical Research</i> , 2020, 53, 1257-1259.	7.6	0
102	Confronting Racism in Chemistry Journals. <i>Journal of Physical Chemistry A</i> , 2020, 124, 5271-5273.	1.1	0
103	Confronting Racism in Chemistry Journals. <i>ACS Energy Letters</i> , 2020, 5, 2291-2293.	8.8	0
104	Confronting Racism in Chemistry Journals. <i>Journal of Chemical Information and Modeling</i> , 2020, 60, 3325-3327.	2.5	0
105	Confronting Racism in Chemistry Journals. <i>Journal of Proteome Research</i> , 2020, 19, 2911-2913.	1.8	0
106	Artificial Intelligence in Drug Discovery: Into the Great Wide Open. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 8651-8652.	2.9	40
107	Confronting Racism in Chemistry Journals. <i>Journal of Physical Chemistry B</i> , 2020, 124, 5335-5337.	1.2	1
108	Update to Our Reader, Reviewer, and Author Communities—April 2020. <i>Journal of Agricultural and Food Chemistry</i> , 2020, 68, 5019-5020.	2.4	0

#	ARTICLE	IF	CITATIONS
109	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Journal of Physical Chemistry B, 2020, 124, 3603-3604.	1.2	0
110	Confronting Racism in Chemistry Journals. Bioconjugate Chemistry, 2020, 31, 1693-1695.	1.8	0
111	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. ACS Applied Nano Materials, 2020, 3, 3960-3961.	2.4	0
112	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Journal of Natural Products, 2020, 83, 1357-1358.	1.5	0
113	Confronting Racism in Chemistry Journals. ACS Synthetic Biology, 2020, 9, 1487-1489.	1.9	0
114	Confronting Racism in Chemistry Journals. Journal of Chemical & Engineering Data, 2020, 65, 3403-3405.	1.0	0
115	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Bioconjugate Chemistry, 2020, 31, 1211-1212.	1.8	0
116	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Journal of Chemical Health and Safety, 2020, 27, 133-134.	1.1	0
117	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Chemical Research in Toxicology, 2020, 33, 1509-1510.	1.7	0
118	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Energy & Fuels, 2020, 34, 5107-5108.	2.5	0
119	Women in Medicinal Chemistry: Ad Maiora!. Journal of Medicinal Chemistry, 2020, 63, 1777-1778.	2.9	3
120	Drug Annotations for a New Decade. Journal of Medicinal Chemistry, 2020, 63, 883-883.	2.9	1
121	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. ACS Applied Bio Materials, 2020, 3, 2873-2874.	2.3	0
122	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Journal of Organic Chemistry, 2020, 85, 5751-5752.	1.7	0
123	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Journal of the American Society for Mass Spectrometry, 2020, 31, 1006-1007.	1.2	0
124	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Accounts of Chemical Research, 2020, 53, 1001-1002.	7.6	0
125	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Biomacromolecules, 2020, 21, 1966-1967.	2.6	0
126	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Chemical Reviews, 2020, 120, 3939-3940.	23.0	0

#	ARTICLE	IF	CITATIONS
127	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Environmental Science & Technology, 2020, 54, 5307-5308.	4.6	0
128	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Langmuir, 2020, 36, 4565-4566.	1.6	0
129	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Molecular Pharmaceutics, 2020, 17, 1445-1446.	2.3	0
130	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. ACS Infectious Diseases, 2020, 6, 891-892.	1.8	0
131	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Crystal Growth and Design, 2020, 20, 2817-2818.	1.4	1
132	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Journal of Medicinal Chemistry, 2020, 63, 4409-4410.	2.9	0
133	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Journal of Physical Chemistry A, 2020, 124, 3501-3502.	1.1	0
134	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Nano Letters, 2020, 20, 2935-2936.	4.5	0
135	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. ACS Sensors, 2020, 5, 1251-1252.	4.0	0
136	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Journal of Chemical Information and Modeling, 2020, 60, 2651-2652.	2.5	0
137	Discovery of M-808 as a Highly Potent, Covalent, Small-Molecule Inhibitor of the Meninâ€™MLL Interaction with Strong <i>In Vivo</i> Antitumor Activity. Journal of Medicinal Chemistry, 2020, 63, 4997-5010.	2.9	23
138	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Industrial & Engineering Chemistry Research, 2020, 59, 8509-8510.	1.8	0
139	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Journal of the American Chemical Society, 2020, 142, 8059-8060.	6.6	3
140	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Inorganic Chemistry, 2020, 59, 5796-5797.	1.9	0
141	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Organometallics, 2020, 39, 1665-1666.	1.1	0
142	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Organic Letters, 2020, 22, 3307-3308.	2.4	0
143	Targeting DCN1-UBC12 Protein-Protein Interaction for Regulation of Neddylation Pathway. Advances in Experimental Medicine and Biology, 2020, 1217, 349-362.	0.8	8
144	Targeted degradation of activating estrogen receptor β ligand-binding domain mutations in human breast cancer. Breast Cancer Research and Treatment, 2020, 180, 611-622.	1.1	43

#	ARTICLE	IF	CITATIONS
145	Confronting Racism in Chemistry Journals. ACS Biomaterials Science and Engineering, 2020, 6, 3690-3692.	2.6	1
146	Confronting Racism in Chemistry Journals. ACS Omega, 2020, 5, 14857-14859.	1.6	1
147	Confronting Racism in Chemistry Journals. ACS Applied Electronic Materials, 2020, 2, 1774-1776.	2.0	0
148	Confronting Racism in Chemistry Journals. Journal of Agricultural and Food Chemistry, 2020, 68, 6941-6943.	2.4	0
149	Confronting Racism in Chemistry Journals. ACS Earth and Space Chemistry, 2020, 4, 961-963.	1.2	0
150	Confronting Racism in Chemistry Journals. Environmental Science and Technology Letters, 2020, 7, 447-449.	3.9	0
151	Confronting Racism in Chemistry Journals. ACS Combinatorial Science, 2020, 22, 327-329.	3.8	0
152	Confronting Racism in Chemistry Journals. ACS Infectious Diseases, 2020, 6, 1529-1531.	1.8	0
153	Confronting Racism in Chemistry Journals. ACS Applied Bio Materials, 2020, 3, 3925-3927.	2.3	0
154	Confronting Racism in Chemistry Journals. Journal of Physical Chemistry C, 2020, 124, 14069-14071.	1.5	0
155	Confronting Racism in Chemistry Journals. ACS Macro Letters, 2020, 9, 1004-1006.	2.3	0
156	Confronting Racism in Chemistry Journals. Molecular Pharmaceutics, 2020, 17, 2229-2231.	2.3	1
157	Confronting Racism in Chemistry Journals. ACS Chemical Neuroscience, 2020, 11, 1852-1854.	1.7	1
158	Confronting Racism in Chemistry Journals. ACS Photonics, 2020, 7, 1586-1588.	3.2	0
159	Confronting Racism in Chemistry Journals. Environmental Science & Technology, 2020, 54, 7735-7737.	4.6	0
160	Confronting Racism in Chemistry Journals. Journal of Chemical Health and Safety, 2020, 27, 198-200.	1.1	0
161	A Potent and Selective Small-Molecule Degradator of STAT3 Achieves Complete Tumor Regression In Vivo. Cancer Cell, 2019, 36, 498-511.e17.	7.7	364
162	Simple Structural Modifications Converting a Bona fide MDM2 PROTAC Degradator into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degradators. Journal of Medicinal Chemistry, 2019, 62, 9471-9487.	2.9	99

#	ARTICLE	IF	CITATIONS
163	Structure-Based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein-Protein Interaction. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 6015-6034.	2.9	20
164	Potent 5-Cyano-6-phenyl-pyrimidin-Based Derivatives Targeting DCN1-UBE2M Interaction. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 5382-5403.	2.9	34
165	The Future Is Now: Artificial Intelligence in Drug Discovery. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 5249-5249.	2.9	3
166	The Direct Molecular Target for Imipridone ONC201 Is Finally Established. <i>Cancer Cell</i> , 2019, 35, 707-708.	7.7	21
167	Small-molecule PROTAC degraders of the Bromodomain and Extra Terminal (BET) proteins - A review. <i>Drug Discovery Today: Technologies</i> , 2019, 31, 43-51.	4.0	92
168	Chemical suppression of specific C-C chemokine signaling pathways enhances cardiac reprogramming. <i>Journal of Biological Chemistry</i> , 2019, 294, 9134-9146.	1.6	20
169	Functional and Mechanistic Interrogation of BET Bromodomain Degraders for the Treatment of Metastatic Castration-resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 4038-4048.	3.2	26
170	Women in Medicinal Chemistry Special Issue Call for Papers. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 3783-3783.	2.9	6
171	A Message from the Editors-in-Chief. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 2215-2216.	2.9	0
172	Characterizing the Therapeutic Potential of a Potent BET Degradator in Merkel Cell Carcinoma. <i>Neoplasia</i> , 2019, 21, 322-330.	2.3	10
173	Development of Highly Potent, Selective, and Cellular Active Triazolo[1,5- <i>a</i>]pyrimidine-Based Inhibitors Targeting the DCN1-UBC12 Protein-Protein Interaction. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 2772-2797.	2.9	59
174	Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degradator of STAT3 Protein. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 11280-11300.	2.9	133
175	Discovery of Highly Potent and Efficient PROTAC Degradators of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 11218-11231.	2.9	138
176	Casein kinase-1 β and 3 stimulate tumor necrosis factor-induced necroptosis through RIPK3. <i>Cell Death and Disease</i> , 2019, 10, 923.	2.7	22
177	Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degradator of Estrogen Receptor (ER). <i>Journal of Medicinal Chemistry</i> , 2019, 62, 1420-1442.	2.9	176
178	Changing the Apoptosis Pathway through Evolutionary Protein Design. <i>Journal of Molecular Biology</i> , 2019, 431, 825-841.	2.0	16
179	Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degradator of Androgen Receptor (AR) for the Treatment of Prostate Cancer. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 941-964.	2.9	269
180	Drug Metabolism and Toxicology Special Issue Call for Papers. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 1077-1077.	2.9	0

#	ARTICLE	IF	CITATIONS
181	Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degradable Capable of Achieving Complete and Durable Tumor Regression. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 448-466.	2.9	211
182	Ablation of Cancer Stem Cells by Therapeutic Inhibition of the MDM2-p53 Interaction in Mucoepidermoid Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 1588-1600.	3.2	17
183	Follicular lymphoma-associated mutations in vacuolar ATPase ATP6V1B2 activate autophagic flux and mTOR. <i>Journal of Clinical Investigation</i> , 2019, 129, 1626-1640.	3.9	23
184	High-Affinity Peptidomimetic Inhibitors of the DCN1-UBC12 Protein-Protein Interaction. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 1934-1950.	2.9	46
185	Resistance to BET Inhibitor Leads to Alternative Therapeutic Vulnerabilities in Castration-Resistant Prostate Cancer. <i>Cell Reports</i> , 2018, 22, 2236-2245.	2.9	60
186	Allosteric Modulators of Drug Targets Special Issue. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 1381-1381.	2.9	0
187	Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein-Protein Interaction. <i>Angewandte Chemie - International Edition</i> , 2018, 57, 1601-1605.	7.2	49
188	Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein-Protein Interaction. <i>Angewandte Chemie</i> , 2018, 130, 1617-1621.	1.6	1
189	Cyclic Peptidic Mimetics of Apollo Peptides Targeting Telomeric Repeat Binding Factor 2 (TRF2) and Apollo Interaction. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 507-511.	1.3	10
190	Discovery of a Small-Molecule Degradable of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 462-481.	2.9	288
191	Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 6110-6120.	2.9	33
192	Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degradable of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 6685-6704.	2.9	204
193	Induction of p53 suppresses chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 2165-2175.	0.6	10
194	Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2017, 77, 2476-2487.	0.4	173
195	Current Medicinal Chemistry Research in India: Progress and Opportunities. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 1619-1619.	2.9	0
196	Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2017, 7, a026245.	2.9	217
197	The Ecstasy and Agony of Assay Interference Compounds. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 2165-2168.	2.9	113
198	The Ecstasy and Agony of Assay Interference Compounds. <i>ACS Central Science</i> , 2017, 3, 143-147.	5.3	78

#	ARTICLE	IF	CITATIONS
199	The Ecstasy and Agony of Assay Interference Compounds. <i>ACS Chemical Biology</i> , 2017, 12, 575-578.	1.6	14
200	The Ecstasy and Agony of Assay Interference Compounds. <i>ACS Chemical Neuroscience</i> , 2017, 8, 420-423.	1.7	8
201	The Ecstasy and Agony of Assay Interference Compounds. <i>Biochemistry</i> , 2017, 56, 1363-1366.	1.2	8
202	The Ecstasy and Agony of Assay Interference Compounds. <i>Journal of Chemical Information and Modeling</i> , 2017, 57, 387-390.	2.5	20
203	The Ecstasy and Agony of Assay Interference Compounds. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 379-382.	1.3	35
204	Allosteric Inactivation of Polycomb Repressive Complex 2 (PRC2) by Inhibiting Its Adapter Protein: Embryonic Ectodomain Development (EED). <i>Journal of Medicinal Chemistry</i> , 2017, 60, 2212-2214.	2.9	10
205	Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9 <i>H</i> -pyrimido[4,5- <i>b</i>]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 3887-3901.	2.9	36
206	Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (WDR5)–Mixed Lineage Leukemia (MLL) Protein–Protein Interaction. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 4818-4839.	2.9	72
207	Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer. <i>Cancer Cell</i> , 2017, 31, 532-548.e7.	7.7	85
208	The Ecstasy and Agony of Assay Interference Compounds. <i>ACS Infectious Diseases</i> , 2017, 3, 259-262.	1.8	4
209	Discovery of 4-((3 <i>R</i> ,4 <i>S</i> ,5 <i>R</i>)-6- ³ -Chloro-4- ² -(3-chloro-2-fluorophenyl)-1-ethyl-2-oxodispiro[cyclohexane-1,2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 2819-2839.	2.9	143
210	A covalently bound inhibitor triggers EZH2 degradation through CHIP-mediated ubiquitination. <i>EMBO Journal</i> , 2017, 36, 1243-1260.	3.5	67
211	A potent small-molecule inhibitor of the DCN1-UBC12 interaction that selectively blocks cullin 3 neddylation. <i>Nature Communications</i> , 2017, 8, 1150.	5.8	71
212	Therapeutic Inhibition of the MDM2–p53 Interaction Prevents Recurrence of Adenoid Cystic Carcinomas. <i>Clinical Cancer Research</i> , 2017, 23, 1036-1048.	3.2	27
213	IAPs protect host target tissues from graft-versus-host disease in mice. <i>Blood Advances</i> , 2017, 1, 1517-1532.	2.5	15
214	Functional Analyses of BTK Mutations in Follicular Lymphoma. <i>Blood</i> , 2017, 130, 647-647.	0.6	0
215	Inducing Protein Degradation as a Therapeutic Strategy. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 5129-5130.	2.9	20
216	MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner. <i>Neoplasia</i> , 2016, 18, 213-222.	2.3	51

#	ARTICLE	IF	CITATIONS
217	Role of BET proteins in castration-resistant prostate cancer. <i>Drug Discovery Today: Technologies</i> , 2016, 19, 29-38.	4.0	15
218	Reactivation of p53 by MDM2 Inhibitor MI-77301 for the Treatment of Endocrine-Resistant Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2887-2893.	1.9	29
219	Targeting Mll1 H3K4 methyltransferase activity to guide cardiac lineage specific reprogramming of fibroblasts. <i>Cell Discovery</i> , 2016, 2, 16036.	3.1	42
220	MLL1 and MLL1 fusion proteins have distinct functions in regulating leukemic transcription program. <i>Cell Discovery</i> , 2016, 2, 16008.	3.1	34
221	Recurrent Mutations in the MTOR Regulator RRAGC in Follicular Lymphoma. <i>Clinical Cancer Research</i> , 2016, 22, 5383-5393.	3.2	36
222	A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer. <i>Investigational New Drugs</i> , 2016, 34, 481-489.	1.2	30
223	Epigenetics: Novel Therapeutics Targeting Epigenetics. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 1247-1248.	2.9	20
224	BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer. <i>Molecular Cancer Research</i> , 2016, 14, 324-331.	1.5	137
225	Design of High-Affinity Stapled Peptides To Target the Repressor Activator Protein 1 (RAP1)/Telomeric Repeat-Binding Factor 2 (TRF2) Protein-Protein Interaction in the Shelterin Complex. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 328-334.	2.9	18
226	Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells. <i>Neoplasia</i> , 2016, 18, 162-171.	2.3	57
227	MLL1 Inhibition Reprograms Epiblast Stem Cells to Naive Pluripotency. <i>Cell Stem Cell</i> , 2016, 18, 481-494.	5.2	57
228	Targeting MDM2 for Treatment of Adenoid Cystic Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 3550-3559.	3.2	13
229	Targeting Inhibitor of Apoptosis Proteins Protects from Bleomycin-Induced Lung Fibrosis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2016, 54, 482-492.	1.4	39
230	Spiromastilactones: A new class of influenza virus inhibitors from deep-sea fungus. <i>European Journal of Medicinal Chemistry</i> , 2016, 108, 229-244.	2.6	46
231	Functional Analyses of V-AtPase Mutations in Follicular Lymphoma. <i>Blood</i> , 2016, 128, 1762-1762.	0.6	0
232	Activating STAT6 mutations in follicular lymphoma. <i>Blood</i> , 2015, 125, 668-679.	0.6	117
233	Epigenetics: Novel Therapeutics Targeting Epigenetics. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 523-524.	2.9	20
234	BH3-mimetic small molecule inhibits the growth and recurrence of adenoid cystic carcinoma. <i>Oral Oncology</i> , 2015, 51, 839-847.	0.8	13

#	ARTICLE	IF	CITATIONS
235	Structure-Based Design of \hat{I}^3 -Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 4927-4939.	2.9	89
236	BET bromodomain inhibition suppresses graft-versus-host disease after allogeneic bone marrow transplantation in mice. <i>Blood</i> , 2015, 125, 2724-2728.	0.6	41
237	Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia <i>In Vitro</i> and <i>In Vivo</i> . <i>Clinical Cancer Research</i> , 2015, 21, 2558-2568.	3.2	49
238	Structure-based design of conformationally constrained cyclic peptidomimetics to target the MLL1-WDR5 protein-protein interaction as inhibitors of the MLL1 methyltransferase activity. <i>Chinese Chemical Letters</i> , 2015, 26, 455-458.	4.8	4
239	Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 1038-1052.	2.9	390
240	Case Study: Discovery of Inhibitors of the MDM2-p53 Protein-Protein Interaction. <i>Methods in Molecular Biology</i> , 2015, 1278, 567-585.	0.4	4
241	Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between <i>In Vitro</i> and <i>In Vivo</i> Drug Treatment. <i>PLoS ONE</i> , 2015, 10, e0128807.	1.1	23
242	SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells. <i>Oncotarget</i> , 2015, 6, 37410-37425.	0.8	18
243	Analysis of 54 Follicular Lymphomas By Whole Exome Sequencing Identifies Multiple Novel Recurrently Mutated Pathways. <i>Blood</i> , 2015, 126, 112-112.	0.6	1
244	Design of Chemically Stable, Potent, and Efficacious MDM2 Inhibitors That Exploit the Retro-Mannich Ring-Opening-Cyclization Reaction Mechanism in Spiro-oxindoles. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 10486-10498.	2.9	57
245	Targeting Apoptosis Pathways for New Cancer Therapeutics. <i>Annual Review of Medicine</i> , 2014, 65, 139-155.	5.0	150
246	Pramipexole Derivatives as Potent and Selective Dopamine D ₃ Receptor Agonists with Improved Human Microsomal Stability. <i>ChemMedChem</i> , 2014, 9, 2653-2660.	1.6	9
247	Absolute Quantitative ¹ H NMR Spectroscopy for Compound Purity Determination. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 9219-9219.	2.9	17
248	SAR405838: An Optimized Inhibitor of MDM2-p53 Interaction That Induces Complete and Durable Tumor Regression. <i>Cancer Research</i> , 2014, 74, 5855-5865.	0.4	261
249	Tranlycypromine Substituted <i>cis</i> -Hydroxycyclobutyl-naphthamides as Potent and Selective Dopamine D ₃ Receptor Antagonists. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 4962-4968.	2.9	47
250	Digital Chemistry in the <i>Journal of Medicinal Chemistry</i> . <i>Journal of Medicinal Chemistry</i> , 2014, 57, 1137-1137.	2.9	9
251	Potent and Selective Small-Molecule Inhibitors of clAP1/2 Proteins Reveal That the Binding of Smac Mimetics to XIAP BIR3 Is Not Required for Their Effective Induction of Cell Death in Tumor Cells. <i>ACS Chemical Biology</i> , 2014, 9, 994-1002.	1.6	30
252	Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. <i>Nature</i> , 2014, 510, 278-282.	13.7	811

#	ARTICLE	IF	CITATIONS
253	Targeting MLL1 H3K4 Methyltransferase Activity in Mixed-Lineage Leukemia. <i>Molecular Cell</i> , 2014, 53, 247-261.	4.5	252
254	Small-molecule SMAC mimetics as new cancer therapeutics. , 2014, 144, 82-95.		160
255	BM-1197: A Novel and Specific Bcl-2/Bcl-xL Inhibitor Inducing Complete and Long-Lasting Tumor Regression In Vivo. <i>PLoS ONE</i> , 2014, 9, e99404.	1.1	71
256	Physiologically based pharmacokinetic and pharmacodynamic modeling of an antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in a mouse xenograft model of human breast cancer. <i>Biopharmaceutics and Drug Disposition</i> , 2013, 34, 348-359.	1.1	16
257	LDK378: A Promising Anaplastic Lymphoma Kinase (ALK) Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 5673-5674.	2.9	46
258	Optimization and validation of mitochondria-based functional assay as a useful tool to identify BH3-like molecules selectively targeting anti-apoptotic Bcl-2 proteins. <i>BMC Biotechnology</i> , 2013, 13, 45.	1.7	5
259	RNF111-Dependent Neddylation Activates DNA Damage-Induced Ubiquitination. <i>Molecular Cell</i> , 2013, 49, 897-907.	4.5	107
260	Structure-Based Design of High-Affinity Macrocyclic Peptidomimetics to Block the Menin-Mixed Lineage Leukemia 1 (MLL1) Protein-Protein Interaction. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 1113-1123.	2.9	78
261	High-Affinity, Small-Molecule Peptidomimetic Inhibitors of MLL1/WDR5 Protein-Protein Interaction. <i>Journal of the American Chemical Society</i> , 2013, 135, 669-682.	6.6	157
262	Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts. <i>Cell Reports</i> , 2013, 4, 1116-1130.	2.9	539
263	A Potent and Highly Efficacious Bcl-2/Bcl-xL Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 3048-3067.	2.9	40
264	Hepatitis C Virus (HCV) Therapies Special Thematic Issue: Call for Papers. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 387-387.	2.9	0
265	Diastereomeric Spirooxindoles as Highly Potent and Efficacious MDM2 Inhibitors. <i>Journal of the American Chemical Society</i> , 2013, 135, 7223-7234.	6.6	200
266	A Potent Small-Molecule Inhibitor of the MDM2-p53 Interaction (MI-888) Achieved Complete and Durable Tumor Regression in Mice. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 5553-5561.	2.9	229
267	A Network of Substrates of the E3 Ubiquitin Ligases MDM2 and HUWE1 Control Apoptosis Independently of p53. <i>Science Signaling</i> , 2013, 6, ra32.	1.6	56
268	A sequence variant in the phospholipase C epsilon C2 domain is associated with esophageal carcinoma and esophagitis. <i>Molecular Carcinogenesis</i> , 2013, 52, 80-86.	1.3	15
269	A Potent Bivalent Smac Mimetic (SM-1200) Achieving Rapid, Complete, and Durable Tumor Regression in Mice. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 3969-3979.	2.9	38
270	The Making of I-BET762, a BET Bromodomain Inhibitor Now in Clinical Development. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 7498-7500.	2.9	82

#	ARTICLE	IF	CITATIONS
271	Identification of a Mutant $\hat{\pm}$ 1 Na/K-ATPase That Pumps but Is Defective in Signal Transduction. <i>Journal of Biological Chemistry</i> , 2013, 288, 13295-13304.	1.6	55
272	The FHA and BRCT domains recognize ADP-ribosylation during DNA damage response. <i>Genes and Development</i> , 2013, 27, 1752-1768.	2.7	132
273	Pyrimido[4,5- <i>d</i>]pyrimidin-4(1 <i>H</i>)-one Derivatives as Selective Inhibitors of EGFR Threonine ⁷⁹⁰ to Methionine ⁷⁹⁰ (T790M) Mutants. <i>Angewandte Chemie - International Edition</i> , 2013, 52, 8387-8390.	7.2	30
274	LRIG1 Modulates Cancer Cell Sensitivity to Smac Mimetics by Regulating TNF $\hat{\pm}$ Expression and Receptor Tyrosine Kinase Signaling. <i>Cancer Research</i> , 2012, 72, 1229-1238.	0.4	32
275	Metronomic Dosing of BH3 Mimetic Small Molecule Yields Robust Antiangiogenic and Antitumor Effects. <i>Cancer Research</i> , 2012, 72, 716-725.	0.4	16
276	p53-mediated heterochromatin reorganization regulates its cell fate decisions. <i>Nature Structural and Molecular Biology</i> , 2012, 19, 478-484.	3.6	49
277	cIAP1 and cIAP2 limit macrophage necroptosis by inhibiting Rip1 and Rip3 activation. <i>Cell Death and Differentiation</i> , 2012, 19, 1791-1801.	5.0	127
278	Targeting Inhibitors of Apoptosis Proteins (IAPs) For New Breast Cancer Therapeutics. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2012, 17, 217-228.	1.0	39
279	Transition in Leadership: Opportunities and Challenges. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 1-1.	2.9	18
280	Correction to Design of Bcl-2 and Bcl-xL Inhibitors with Subnanomolar Binding Affinities Based upon a New Scaffold. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 5987-5987.	2.9	1
281	Structure-Based Discovery of BM-957 as a Potent Small-Molecule Inhibitor of Bcl-2 and Bcl-xL Capable of Achieving Complete Tumor Regression. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 8502-8514.	2.9	50
282	High-affinity and selective dopamine D3 receptor full agonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 5612-5617.	1.0	12
283	Design of Bcl-2 and Bcl-xL Inhibitors with Subnanomolar Binding Affinities Based upon a New Scaffold. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 4664-4682.	2.9	62
284	AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins, inhibits progression of human ovarian cancer. <i>Cancer Biology and Therapy</i> , 2012, 13, 804-811.	1.5	54
285	Analysis of Flexibility and Hotspots in Bcl-xL and Mcl-1 Proteins for the Design of Selective Small-Molecule Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2012, 3, 308-312.	1.3	32
286	Bivalent Smac Mimetics with a Diazabicyclic Core as Highly Potent Antagonists of XIAP and cIAP1/2 and Novel Anticancer Agents. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 106-114.	2.9	35
287	Design of Triazole-Stapled BCL9 $\hat{\pm}$ -Helical Peptides to Target the $\hat{\pm}$ -Catenin/B-Cell CLL/lymphoma 9 (BCL9) Protein-Protein Interaction. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 1137-1146.	2.9	221
288	Hepatic TRAF2 Regulates Glucose Metabolism Through Enhancing Glucagon Responses. <i>Diabetes</i> , 2012, 61, 566-573.	0.3	50

#	ARTICLE	IF	CITATIONS
289	Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapeutics. <i>Topics in Medicinal Chemistry</i> , 2012, , 57-79.	0.4	60
290	Alzheimer's Disease Special Thematic Issue: Call for Papers. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 2914-2914.	2.9	0
291	Smac-mimetic compound SM-164 induces radiosensitization in breast cancer cells through activation of caspases and induction of apoptosis. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 189-199.	1.1	32
292	AM-8553: A Novel MDM2 Inhibitor with a Promising Outlook for Potential Clinical Development. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 4934-4935.	2.9	32
293	Structure-Based Design of Potent Bcl-2/Bcl-xL Inhibitors with Strong in Vivo Antitumor Activity. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 6149-6161.	2.9	49
294	Effects of pramipexole on the reinforcing effectiveness of stimuli that were previously paired with cocaine reinforcement in rats. <i>Psychopharmacology</i> , 2012, 219, 123-135.	1.5	23
295	CSAR Benchmark Exercise of 2010: Selection of the Protein-Ligand Complexes. <i>Journal of Chemical Information and Modeling</i> , 2011, 51, 2036-2046.	2.5	133
296	Correction to CSAR Benchmark Exercise of 2010: Selection of the Protein-Ligand Complexes. <i>Journal of Chemical Information and Modeling</i> , 2011, 51, 2146-2146.	2.5	4
297	CSAR Benchmark Exercise of 2010: Combined Evaluation Across All Submitted Scoring Functions. <i>Journal of Chemical Information and Modeling</i> , 2011, 51, 2115-2131.	2.5	133
298	A Potent and Orally Active Antagonist (SM-406/AT-406) of Multiple Inhibitor of Apoptosis Proteins (IAPs) in Clinical Development for Cancer Treatment. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 2714-2726.	2.9	241
299	Potent Bivalent Smac Mimetics: Effect of the Linker on Binding to Inhibitor of Apoptosis Proteins (IAPs) and Anticancer Activity. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 3306-3318.	2.9	44
300	Hydrophobic Binding Hot Spots of Bcl-xL Protein-Protein Interfaces by Cosolvent Molecular Dynamics Simulation. <i>ACS Medicinal Chemistry Letters</i> , 2011, 2, 280-284.	1.3	51
301	CJ-1639: A Potent and Highly Selective Dopamine D3 Receptor Full Agonist. <i>ACS Medicinal Chemistry Letters</i> , 2011, 2, 620-625.	1.3	19
302	Behavioral sensitization to cocaine in rats: evidence for temporal differences in dopamine D3 and D2 receptor sensitivity. <i>Psychopharmacology</i> , 2011, 215, 609-620.	1.5	27
303	Radiosensitization of Head and Neck Squamous Cell Carcinoma by a SMAC-Mimetic Compound, SM-164, Requires Activation of Caspases. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 658-669.	1.9	41
304	In Vitro Metabolism of 17-(Dimethylaminoethylamino)-17-demethoxygeldanamycin in Human Liver Microsomes. <i>Drug Metabolism and Disposition</i> , 2011, 39, 627-635.	1.7	10
305	Therapeutic Potential and Molecular Mechanism of a Novel, Potent, Nonpeptide, Smac Mimetic SM-164 in Combination with TRAIL for Cancer Treatment. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 902-914.	1.9	64
306	A Dual-Readout FRET Assay That Combines Fluorescence Resonance Energy Transfer and Fluorescence Polarization for Monitoring Bimolecular Interactions. <i>Assay and Drug Development Technologies</i> , 2011, 9, 382-393.	0.6	17

#	ARTICLE	IF	CITATIONS
307	Abstract LB-204: Highly potent and optimized small-molecule inhibitors of MDM2 achieve complete tumor regression in animal models of solid tumors and leukemia.. <i>Cancer Research</i> , 2011, 71, LB-204-LB-204.	0.4	3
308	Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. <i>Blood</i> , 2010, 116, 71-80.	0.6	82
309	AT-101 (gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model. <i>Journal of Cellular Biochemistry</i> , 2010, 110, 1187-1194.	1.2	21
310	Cyclopeptide Smac mimetics as antagonists of IAP proteins. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 3043-3046.	1.0	33
311	Metronomic Small Molecule Inhibitor of Bcl-2 (TW-37) Is Antiangiogenic and Potentiates the Antitumor Effect of Ionizing Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 879-887.	0.4	16
312	Case Study: Inhibitors of the MDM2-p53 Protein-Protein Interaction. , 2010, , 273-293.		0
313	Smac Mimetic Compounds Potentiate Interleukin-1 β -mediated Cell Death. <i>Journal of Biological Chemistry</i> , 2010, 285, 40612-40623.	1.6	19
314	Split Renilla Luciferase Protein Fragment-assisted Complementation (SRL-PFAC) to Characterize Hsp90-Cdc37 Complex and Identify Critical Residues in Protein/Protein Interactions. <i>Journal of Biological Chemistry</i> , 2010, 285, 21023-21036.	1.6	33
315	Design of Small-Molecule Smac Mimetics as IAP Antagonists. <i>Current Topics in Microbiology and Immunology</i> , 2010, 348, 89-113.	0.7	54
316	Analysis of the Binding of Mixed Lineage Leukemia 1 (MLL1) and Histone 3 Peptides to WD Repeat Domain 5 (WDR5) for the Design of Inhibitors of the MLL1-WDR5 Interaction. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 5179-5185.	2.9	61
317	Computational Analysis of Protein Hotspots. <i>ACS Medicinal Chemistry Letters</i> , 2010, 1, 125-129.	1.3	28
318	MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function. <i>European Journal of Cancer</i> , 2010, 46, 1122-1131.	1.3	65
319	Structure-Based Design of Conformationally Constrained, Cell-Permeable STAT3 Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2010, 1, 85-89.	1.3	80
320	Superparamagnetic Iron Oxide Nanotheranostics for Targeted Cancer Cell Imaging and pH-Dependent Intracellular Drug Release. <i>Molecular Pharmaceutics</i> , 2010, 7, 1974-1984.	2.3	124
321	Nonpeptidic and Potent Small-Molecule Inhibitors of cIAP-1/2 and XIAP Proteins. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 6361-6367.	2.9	43
322	Proerectile Effects of Dopamine D ₂ -Like Agonists Are Mediated by the D ₃ Receptor in Rats and Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 329, 210-217.	1.3	41
323	TW-37, a Small-Molecule Inhibitor of Bcl-2, Inhibits Cell Growth and Induces Apoptosis in Pancreatic Cancer: Involvement of Notch-1 Signaling Pathway. <i>Cancer Research</i> , 2009, 69, 2757-2765.	0.4	78
324	Cardiac Glycosides Inhibit p53 Synthesis by a Mechanism Relieved by Src or MAPK Inhibition. <i>Cancer Research</i> , 2009, 69, 6556-6564.	0.4	105

#	ARTICLE	IF	CITATIONS
325	TW-37, a small-molecule inhibitor of Bcl-2, mediates S-phase cell cycle arrest and suppresses head and neck tumor angiogenesis. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 893-903.	1.9	50
326	Efficient synthesis of phosphotyrosine building blocks using imidazolium trifluoroacetate. <i>Tetrahedron Letters</i> , 2009, 50, 6691-6692.	0.7	6
327	Design, synthesis, and evaluation of peptidomimetics containing Freidinger lactams as STAT3 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 1733-1736.	1.0	23
328	Design, Synthesis, and Evaluation of Potent, Nonpeptidic Mimetics of Second Mitochondria-Derived Activator of Caspases. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 593-596.	2.9	40
329	Analysis of the Interaction of BCL9 with β -Catenin and Development of Fluorescence Polarization and Surface Plasmon Resonance Binding Assays for this Interaction. <i>Biochemistry</i> , 2009, 48, 9534-9541.	1.2	35
330	Importance of Ligand Reorganization Free Energy in Protein-Ligand Binding-Affinity Prediction. <i>Journal of the American Chemical Society</i> , 2009, 131, 13709-13721.	6.6	67
331	Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy. <i>Annual Review of Pharmacology and Toxicology</i> , 2009, 49, 223-241.	4.2	547
332	An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals. <i>Molecular Cancer</i> , 2009, 8, 115.	7.9	71
333	Potent and Orally Active Small-Molecule Inhibitors of the MDM2-p53 Interaction. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 7970-7973.	2.9	169
334	Dopamine D2/3 receptor partial agonists failed to produce antidepressant-like effects in the rat forced swim test. <i>FASEB Journal</i> , 2009, 23, 745.6.	0.2	0
335	Design and characterization of bivalent Smac-based peptides as antagonists of XIAP and development and validation of a fluorescence polarization assay for XIAP containing both BIR2 and BIR3 domains. <i>Analytical Biochemistry</i> , 2008, 374, 87-98.	1.1	45
336	Design of Small-Molecule Peptidic and Nonpeptidic Smac Mimetics. <i>Accounts of Chemical Research</i> , 2008, 41, 1264-1277.	7.6	144
337	Apogossypolone promotes the apoptosis of bladder cancer cells in vitro. <i>Pharmacological Research</i> , 2008, 58, 323-331.	3.1	37
338	Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model. <i>Molecular Cancer</i> , 2008, 7, 20.	7.9	68
339	Structure-Based Design, Synthesis, Evaluation, and Crystallographic Studies of Conformationally Constrained Smac Mimetics as Inhibitors of the X-linked Inhibitor of Apoptosis Protein (XIAP). <i>Journal of Medicinal Chemistry</i> , 2008, 51, 7169-7180.	2.9	82
340	Design, Synthesis, and Evaluation of Tricyclic, Conformationally Constrained Small-Molecule Mimetics of Second Mitochondria-Derived Activator of Caspases. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 7352-7355.	2.9	36
341	Targeting the MDM2-p53 Interaction for Cancer Therapy. <i>Clinical Cancer Research</i> , 2008, 14, 5318-5324.	3.2	302
342	Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 1772-1781.	1.9	181

#	ARTICLE	IF	CITATIONS
343	Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. <i>Blood</i> , 2008, 111, 1584-1593.	0.6	107
344	Design, Synthesis, and Evaluation of Potent and Selective Ligands for the Dopamine 3 (D ₃) Receptor with a Novel in Vivo Behavioral Profile. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 5905-5908.	2.9	29
345	Acylpyrogallols as Inhibitors of Antiapoptotic Bcl-2 Proteins. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 717-720.	2.9	77
346	Potent, Orally Bioavailable Diazabicyclic Small-Molecule Mimetics of Second Mitochondria-Derived Activator of Caspases. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 8158-8162.	2.9	50
347	Interaction of a Cyclic, Bivalent Smac Mimetic with the X-Linked Inhibitor of Apoptosis Protein. <i>Biochemistry</i> , 2008, 47, 9811-9824.	1.2	52
348	A small molecule that disrupts Mdm2-p53 binding activates p53, induces apoptosis, and sensitizes lung cancer cells to chemotherapy. <i>Cancer Biology and Therapy</i> , 2008, 7, 845-852.	1.5	36
349	The pre-clinical development of MDM2 inhibitors in chronic lymphocytic leukemia uncovers a central role for p53 status in sensitivity to Mdm2 inhibitor-mediated apoptosis. <i>Cell Cycle</i> , 2008, 7, 971-979.	1.3	25
350	Anti-oxidant treatment enhances anti-tumor cytotoxicity of (-)-gossypol. <i>Cancer Biology and Therapy</i> , 2008, 7, 767-776.	1.5	17
351	Apogossypolone, a nonpeptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells in vitro and in vivo. <i>Cancer Biology and Therapy</i> , 2008, 7, 1418-1426.	1.5	40
352	Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 3933-3938.	3.3	641
353	Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 1533-1542.	1.9	87
354	Combined Targeting of Epidermal Growth Factor Receptor, Signal Transducer and Activator of Transcription-3, and Bcl-X _L Enhances Antitumor Effects in Squamous Cell Carcinoma of the Head and Neck. <i>Molecular Pharmacology</i> , 2008, 73, 1632-1642.	1.0	64
355	Critical role of prostate apoptosis response-4 in determining the sensitivity of pancreatic cancer cells to small-molecule inhibitor-induced apoptosis. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 2884-2893.	1.9	37
356	SM-164: A Novel, Bivalent Smac Mimetic That Induces Apoptosis and Tumor Regression by Concurrent Removal of the Blockade of cIAP-1/2 and XIAP. <i>Cancer Research</i> , 2008, 68, 9384-9393.	0.4	177
357	p27 degradation by an ellipticinium series of compound via ubiquitin-proteasome pathway. <i>Cancer Biology and Therapy</i> , 2007, 6, 360-366.	1.5	7
358	Preclinical Studies of TW-37, a New Nonpeptidic Small-Molecule Inhibitor of Bcl-2, in Diffuse Large Cell Lymphoma Xenograft Model Reveal Drug Action on Both Bcl-2 and Mcl-1. <i>Clinical Cancer Research</i> , 2007, 13, 2226-2235.	3.2	147
359	Bioinformatics-based discovery and characterization of an AKT-selective inhibitor 9-chloro-2-methylellypticinium acetate (CMEP) in breast cancer cells. <i>Cancer Letters</i> , 2007, 252, 244-258.	3.2	10
360	Small Molecule Inhibitors of the MDM2-p53 Interaction Discovered by Ensemble-Based Receptor Models. <i>Journal of the American Chemical Society</i> , 2007, 129, 12809-12814.	6.6	133

#	ARTICLE	IF	CITATIONS
361	Analysis of Ligand-Bound Water Molecules in High-Resolution Crystal Structures of Protein~Ligand Complexes. <i>Journal of Chemical Information and Modeling</i> , 2007, 47, 668-675.	2.5	156
362	Pyrogallol-Based Molecules as Potent Inhibitors of the Antiapoptotic Bcl-2 Proteins. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 1723-1726.	2.9	44
363	Design, Synthesis, and Characterization of a Potent, Nonpeptide, Cell-Permeable, Bivalent Smac Mimetic That Concurrently Targets Both the BIR2 and BIR3 Domains in XIAP. <i>Journal of the American Chemical Society</i> , 2007, 129, 15279-15294.	6.6	191
364	Structure-Based Design of Flavonoid Compounds As a New Class of Small-Molecule Inhibitors of the Anti-apoptotic Bcl-2 Proteins. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 3163-3166.	2.9	39
365	($\hat{I}^{\pm}/\hat{I}^{2+}/\hat{I}^{\pm}$)-Peptide Antagonists of BH3 Domain/Bcl-xL Recognition:~ Toward General Strategies for Foldamer-Based Inhibition of Protein~Protein Interactions. <i>Journal of the American Chemical Society</i> , 2007, 129, 139-154.	6.6	160
366	Design and synthesis of a new, conformationally constrained, macrocyclic small-molecule inhibitor of STAT3 via ~click chemistry~. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 3939-3942.	1.0	54
367	Blockade of AKT activation in prostate cancer cells with a small molecule inhibitor, 9-chloro-2-methylellipticinium acetate (CMEP). <i>Biochemical Pharmacology</i> , 2007, 73, 15-24.	2.0	15
368	Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists. <i>Psychopharmacology</i> , 2007, 193, 159-170.	1.5	119
369	A novel Bcl-2 small molecule inhibitor 4-(3-methoxy-phenylsulfanyl)-7-nitro-benzofurazan-3-oxide (MNB)-induced apoptosis in leukemia cells. <i>Annals of Hematology</i> , 2007, 86, 471-481.	0.8	14
370	Comprehensive Biomarker and Genomic Analysis Identifies p53 Status as the Major Determinant of Response to MDM2 Inhibitors in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2007, 110, 224-224.	0.6	0
371	Evaluation of TW-37, a pan Bcl-2 Proteins Small-Molecule Inhibitor, Against Spectrum of Human B-Cell Lines and Patient-Derived Samples.. <i>Blood</i> , 2007, 110, 4521-4521.	0.6	2
372	Design, Synthesis, and Evaluation of a Potent, Cell-Permeable, Conformationally Constrained Second Mitochondria Derived Activator of Caspase (Smac) Mimetic. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 7916-7920.	2.9	101
373	Binding Free Energy Contributions of Interfacial Waters in HIV-1 Protease/Inhibitor Complexes. <i>Journal of the American Chemical Society</i> , 2006, 128, 11830-11839.	6.6	87
374	Structure-Based Design of Potent Small-Molecule Inhibitors of Anti-Apoptotic Bcl-2 Proteins. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 6139-6142.	2.9	274
375	Discovery of a Nanomolar Inhibitor of the Human Murine Double Minute 2 (MDM2)~p53 Interaction through an Integrated, Virtual Database Screening Strategy. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 3759-3762.	2.9	124
376	M-Score:~ A Knowledge-Based Potential Scoring Function Accounting for Protein Atom Mobility. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 5903-5911.	2.9	63
377	(~)-Gossypol Inhibits Growth and Promotes Apoptosis of Human Head and Neck Squamous Cell Carcinoma In Vivo. <i>Neoplasia</i> , 2006, 8, 163-172.	2.3	106
378	Computational Elucidation of the Structural Basis of Ligand Binding to the Dopamine 3 Receptor through Docking and Homology Modeling. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 4470-4476.	2.9	21

#	ARTICLE	IF	CITATIONS
379	Structure-Based Design of Spiro-oxindoles as Potent, Specific Small-Molecule Inhibitors of the MDM2-p53 Interaction. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 3432-3435.	2.9	647
380	Chapter 11 Recent Advances in Design of Small-Molecule Ligands to Target Protein-Protein Interactions. <i>Annual Reports in Computational Chemistry</i> , 2006, , 197-219.	0.9	1
381	Design of novel hexahydropyrazinoquinolines as potent and selective dopamine D3 receptor ligands with improved solubility. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 443-446.	1.0	23
382	Design, synthesis, and characterization of new embelin derivatives as potent inhibitors of X-linked inhibitor of apoptosis protein. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 5805-5808.	1.0	67
383	Design and synthesis of a 1,5-diazabicyclo[6,3,0] dodecane amino acid derivative as a novel dipeptide reverse-turn mimetic. <i>Tetrahedron Letters</i> , 2006, 47, 4769-4770.	0.7	10
384	Discovery of a Novel Nonphosphorylated Pentapeptide Motif Displaying High Affinity for Grb2-SH2 Domain by the Utilization of 3-Substituted Tyrosine Derivatives. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 1585-1596.	2.9	47
385	A small molecule compound inhibits AKT pathway in ovarian cancer cell lines. <i>Gynecologic Oncology</i> , 2006, 100, 308-317.	0.6	36
386	A Novel BH3 Mimetic Reveals a Mitogen-Activated Protein Kinase-Dependent Mechanism of Melanoma Cell Death Controlled by p53 and Reactive Oxygen Species. <i>Cancer Research</i> , 2006, 66, 11348-11359.	0.4	138
387	Antiangiogenic Effect of TW37, a Small-Molecule Inhibitor of Bcl-2. <i>Cancer Research</i> , 2006, 66, 8698-8706.	0.4	79
388	Blockage of Epidermal Growth Factor Receptor-Phosphatidylinositol 3-Kinase-AKT Signaling Increases Radiosensitivity of K-RAS Mutated Human Tumor Cells In vitro by Affecting DNA Repair. <i>Clinical Cancer Research</i> , 2006, 12, 4119-4126.	3.2	196
389	Identification of the Fibroblast Growth Factor (FGF)-interacting Domain in a Secreted FGF-binding Protein by Phage Display. <i>Journal of Biological Chemistry</i> , 2006, 281, 1137-1144.	1.6	31
390	A Systematic Analysis of the Effect of Small-Molecule Binding on Protein Flexibility of the Ligand-Binding Sites. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 5648-5650.	2.9	17
391	Nonpeptidic Small-Molecule Inhibitor of Bcl-2 and Bcl-XL, (???)-Gossypol, Enhances Biological Effect of Genistein Against BxPC-3 Human Pancreatic Cancer Cell Line. <i>Pancreas</i> , 2005, 31, 317-324.	0.5	56
392	Efficient synthesis of isoflavone analogues via a Suzuki coupling reaction. <i>Tetrahedron Letters</i> , 2005, 46, 3707-3709.	0.7	29
393	Synthesis of spirooxindoles via asymmetric 1,3-dipolar cycloaddition. <i>Tetrahedron Letters</i> , 2005, 46, 5949-5951.	0.7	59
394	Design and synthesis of a potent biotinylated Smac mimetic. <i>Tetrahedron Letters</i> , 2005, 46, 7015-7018.	0.7	4
395	Structure-based design, synthesis and biochemical testing of novel and potent Smac peptido-mimetics. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 793-797.	1.0	53
396	Design, synthesis and structure-activity relationship studies of hexahydropyrazinoquinolines as a novel class of potent and selective dopamine receptor 3 (D3) ligands. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 1701-1705.	1.0	21

#	ARTICLE	IF	CITATIONS
397	Identification of Novel Neuroprotective Agents Using Pharmacophore Modeling. <i>Chemistry and Biodiversity</i> , 2005, 2, 1564-1570.	1.0	6
398	An Extensive Test for 14 Scoring Functions Using the PDBbind Refined Set of 800 Protein-Ligand Complexes.. <i>ChemInform</i> , 2005, 36, no.	0.1	0
399	Design, Synthesis, and Evaluation of Hexahydrobenz[f]isoquinolines as a Novel Class of Dopamine 3 Receptor Ligands.. <i>ChemInform</i> , 2005, 36, no.	0.1	0
400	Design, Synthesis and Structure-Activity Relationship Studies of Hexahydropyrazinoquinolines as a Novel Class of Potent and Selective Dopamine Receptor 3 (D3) Ligands.. <i>ChemInform</i> , 2005, 36, no.	0.1	0
401	Efficient Synthesis of Isoflavone Analogues via a Suzuki Coupling Reaction.. <i>ChemInform</i> , 2005, 36, no.	0.1	0
402	Synthesis of Spirooxindoles via Asymmetric 1,3-Dipolar Cycloaddition.. <i>ChemInform</i> , 2005, 36, no.	0.1	0
403	A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 4700-4705.	3.3	460
404	Bcl-2 Acts in a Proangiogenic Signaling Pathway through Nuclear Factor- κ B and CXC Chemokines. <i>Cancer Research</i> , 2005, 65, 5063-5069.	0.4	101
405	The PDBbind Database: Methodologies and Updates. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 4111-4119.	2.9	632
406	Chimeric (β + β)-Peptide Ligands for the BH3-Recognition Cleft of Bcl-xL: Critical Role of the Molecular Scaffold in Protein Surface Recognition. <i>Journal of the American Chemical Society</i> , 2005, 127, 11966-11968.	6.6	166
407	Reversal of cisplatin resistance with a BH3 mimetic, (β)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 1096-1104.	1.9	116
408	Enantiomerically Pure Hexahydropyrazinoquinolines as Potent and Selective Dopamine 3 Subtype Receptor Ligands. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 3171-3181.	2.9	24
409	Structure-Based Design of Potent Non-Peptide MDM2 Inhibitors. <i>Journal of the American Chemical Society</i> , 2005, 127, 10130-10131.	6.6	608
410	CHMIS-C: A Comprehensive Herbal Medicine Information System for Cancer. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 1481-1488.	2.9	52
411	Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(β)-gossypol] against diffuse large cell lymphoma. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 13-21.	1.9	67
412	(β)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-X(L)-mediated apoptosis resistance. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 23-31.	1.9	59
413	(β)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 197-205.	1.9	90
414	Breast Cancer Cells Can Evade Apoptosis-Mediated Selective Killing by a Novel Small Molecule Inhibitor of Bcl-2. <i>Cancer Research</i> , 2004, 64, 7947-7953.	0.4	85

#	ARTICLE	IF	CITATIONS
415	In vitro Effects of the BH3 Mimetic, (âˆ™)-Gossypol, on Head and Neck Squamous Cell Carcinoma Cells. <i>Clinical Cancer Research</i> , 2004, 10, 7757-7763.	3.2	130
416	Web-Based Tools for Mining the NCI Databases for Anticancer Drug Discovery.. <i>ChemInform</i> , 2004, 35, no.	0.1	0
417	An efficient synthesis of optically pure (S)-2-functionalized 1,2,3,4-tetrahydroquinoline. <i>Tetrahedron Letters</i> , 2004, 45, 1027-1029.	0.7	6
418	Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization. <i>Analytical Biochemistry</i> , 2004, 332, 261-273.	1.1	479
419	Design, synthesis, and evaluation of hexahydrobenz[f]isoquinolines as a novel class of dopamine 3 receptor ligands. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 5813-5816.	1.0	7
420	Solution Conformations of Wild-Type and Mutated Bak BH3 Peptides via Dynamical Conformational Sampling and Implication to Their Binding to Antiapoptotic Bcl-2 Proteins. <i>Journal of Physical Chemistry B</i> , 2004, 108, 1467-1477.	1.2	6
421	Formation of a Novel Reversible Cytochrome P450 Spectral Intermediate:â€‰ Role of Threonine 303 in P450 2E1 Inactivation. <i>Biochemistry</i> , 2004, 43, 11942-11952.	1.2	18
422	Structure-Based Discovery of Nonpeptidic Small Organic Compounds To Block the T Cell Response to Myelin Basic Protein. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 4989-4997.	2.9	34
423	Structure-Based Design of Potent, Conformationally Constrained Smac Mimetics. <i>Journal of the American Chemical Society</i> , 2004, 126, 16686-16687.	6.6	154
424	Structure-Based Design, Synthesis, and Evaluation of Conformationally Constrained Mimetics of the Second Mitochondria-Derived Activator of Caspase That Target the X-Linked Inhibitor of Apoptosis Protein/Caspase-9 Interaction Site. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 4147-4150.	2.9	135
425	Discovery of Embelin as a Cell-Permeable, Small-Molecular Weight Inhibitor of XIAP through Structure-Based Computational Screening of a Traditional Herbal Medicine Three-Dimensional Structure Database. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 2430-2440.	2.9	335
426	Web-Based Tools for Mining the NCI Databases for Anticancer Drug Discovery. <i>Journal of Chemical Information and Computer Sciences</i> , 2004, 44, 249-257.	2.8	28
427	An Extensive Test of 14 Scoring Functions Using the PDBbind Refined Set of 800 Proteinâˆ™Ligand Complexes. <i>Journal of Chemical Information and Computer Sciences</i> , 2004, 44, 2114-2125.	2.8	234
428	The PDBbind Database:â€‰ Collection of Binding Affinities for Proteinâˆ™Ligand Complexes with Known Three-Dimensional Structures. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 2977-2980.	2.9	787
429	Targeting Bcl-2 and Bcl-X with nonpeptidic small-molecule antagonists. <i>Seminars in Oncology</i> , 2003, 30, 133-142.	0.8	171
430	Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells. <i>Biochemical Pharmacology</i> , 2003, 66, 93-103.	2.0	159
431	Pharmacophore-Based discovery of substituted pyridines as novel dopamine transporter inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 513-517.	1.0	78
432	2,3-Disubstituted quinuclidines as a novel class of dopamine transporter inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2003, 11, 1123-1136.	1.4	8

#	ARTICLE	IF	CITATIONS
433	Molecular Modeling of the Three-Dimensional Structure of Dopamine 3 (D3) Subtype Receptor:â€‰Discovery of Novel and Potent D3 Ligands through a Hybrid Pharmacophore- and Structure-Based Database Searching Approach. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 4377-4392.	2.9	138
434	Comparative Evaluation of 11 Scoring Functions for Molecular Docking. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 2287-2303.	2.9	834
435	Structural Basis of RasGRP Binding to High-Affinity PKC Ligands. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 853-860.	2.9	21
436	Competitive and Reversible Binding of a Guest Molecule to Its Host in Aqueous Solution through Molecular Dynamics Simulation:Â Benzyl Alcohol/Î²-Cyclodextrin System. <i>Journal of Physical Chemistry B</i> , 2002, 106, 4863-4872.	1.2	40
437	A Web-Based 3D-Database Pharmacophore Searching Tool for Drug Discovery. <i>Journal of Chemical Information and Computer Sciences</i> , 2002, 42, 192-198.	2.8	24
438	Molecular Modeling of the Interactions of Glutamate Carboxypeptidase II with Its Potent NAAG-Based Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 4140-4152.	2.9	39
439	Direct Observation of the Folding and Unfolding of a Î²-Hairpin in Explicit Water through Computer Simulation. <i>Journal of the American Chemical Society</i> , 2002, 124, 5282-5283.	6.6	63
440	Discovery of substituted 3,4-Diphenyl-thiazoles as a novel class of monoamine transporter inhibitors through 3-D pharmacophore search using a new pharmacophore model derived from mazindol. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2002, 12, 1775-1778.	1.0	15
441	Further development and validation of empirical scoring functions for structure-based binding affinity prediction. <i>Journal of Computer-Aided Molecular Design</i> , 2002, 16, 11-26.	1.3	1,012
442	Discovery of Substituted 3,4-Diphenyl-thiazoles as a Novel Class of Monoamine Transporter Inhibitors Through 3-D Pharmacophore Search Using a New Pharmacophore Model Derived from Mazindol.. <i>ChemInform</i> , 2002, 33, 252-252.	0.1	0
443	How Does Consensus Scoring Work for Virtual Library Screening? An Idealized Computer Experiment. <i>Journal of Chemical Information and Computer Sciences</i> , 2001, 41, 1422-1426.	2.8	279
444	Comparison of the NCI Open Database with Seven Large Chemical Structural Databases. <i>Journal of Chemical Information and Computer Sciences</i> , 2001, 41, 702-712.	2.8	202
445	Discovery of Small-Molecule Inhibitors of Bcl-2 through Structure-Based Computer Screening. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 4313-4324.	2.9	325
446	Structural Basis of Binding of High-Affinity Ligands to Protein Kinase C:Â Prediction of the Binding Modes through a New Molecular Dynamics Method and Evaluation by Site-Directed Mutagenesis. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 1690-1701.	2.9	48
447	Molecular Modeling Studies of the Akt PH Domain and Its Interaction with Phosphoinositides. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 898-908.	2.9	50
448	Iridals Are a Novel Class of Ligands for Phorbol Ester Receptors with Modest Selectivity for the RasGRP Receptor Subfamilyâ€. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 3872-3880.	2.9	42
449	Helix Folding of an Alanine-Based Peptide in Explicit Water. <i>Journal of Physical Chemistry B</i> , 2001, 105, 2227-2235.	1.2	51
450	Pharmacophore-Based discovery, synthesis, and biological evaluation of 4-phenyl-1-arylalkyl piperidines as dopamine transporter inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2001, 11, 495-500.	1.0	26

#	ARTICLE	IF	CITATIONS
451	Rational design, synthesis, and biological evaluation of rigid pyrrolidone analogues as potential inhibitors of prostate cancer cell growth. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2001, 11, 955-959.	1.0	33
452	Pharmacophore-based discovery of 3,4-disubstituted pyrrolidines as a novel class of monoamine transporter inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2001, 11, 1113-1118.	1.0	49
453	Synthesis and evaluation of the sunflower derived trypsin inhibitor as a potent inhibitor of the type II transmembrane serine protease, matriptase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2001, 11, 2515-2519.	1.0	83
454	Structure-Based Approach for the Discovery of Bis-benzamidines as Novel Inhibitors of Matriptase. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 1349-1355.	2.9	80
455	Molecular Modeling, Structure-Activity Relationships and Functional Antagonism Studies of 4-Hydroxy-1-methyl-4-(4-methylphenyl)-3-piperidyl 4-Methylphenyl Ketones as a Novel Class of Dopamine Transporter Inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2001, 9, 1753-1764.	1.4	18
456	Phorbol Esters and Related Analogs Regulate the Subcellular Localization of β 2-Chimaerin, a Non-protein Kinase C Phorbol Ester Receptor. <i>Journal of Biological Chemistry</i> , 2001, 276, 18303-18312.	1.6	62
457	Role of Hydrophobic Residues in the C1b Domain of Protein Kinase C β on Ligand and Phospholipid Interactions. <i>Journal of Biological Chemistry</i> , 2001, 276, 19580-19587.	1.6	43
458	Bicyclic Peptide Inhibitors of an Epithelial Cell-Derived Transmembrane Protease, Matriptase. , 2001, , 561-562.		0
459	Discovery of a Novel Dopamine Transporter Inhibitor, 4-Hydroxy-1-methyl-4-(4-methylphenyl)-3-piperidyl 4-Methylphenyl Ketone, as a Potential Cocaine Antagonist through 3D-Database Pharmacophore Searching. <i>Molecular Modeling, Structure-Activity Relationships, and Behavioral Pharmacological Studies. Journal of Medicinal Chemistry</i> , 2000, 43, 351-360.	2.9	68
460	Application of a Molecular Dynamics Simulation Method with a Generalized Effective Potential to the Flexible Molecular Docking Problems. <i>Journal of Physical Chemistry B</i> , 2000, 104, 354-359.	1.2	63
461	Folding Studies of a Linear Pentamer Peptide Adopting a Reverse Turn Conformation in Aqueous Solution through Molecular Dynamics Simulation. <i>Journal of Physical Chemistry B</i> , 2000, 104, 8023-8034.	1.2	28
462	3-(Hydroxymethyl)-Bearing Phosphatidylinositol Ether Lipid Analogues and Carbonate Surrogates Block PI3-K, Akt, and Cancer Cell Growth. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 3045-3051.	2.9	197
463	Enhancing systematic motion in molecular dynamics simulation. <i>Journal of Chemical Physics</i> , 1999, 110, 9401-9410.	1.2	61
464	Folding of a 16-residue helical peptide using molecular dynamics simulation with Tsallis effective potential. <i>Journal of Chemical Physics</i> , 1999, 111, 4359-4361.	1.2	38
465	beta 2-Chimaerin is a novel target for diacylglycerol: Binding properties and changes in subcellular localization mediated by ligand binding to its C1 domain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 11854-11859.	3.3	91
466	Synthesis and protein kinase C binding activity of benzolactam-V7. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1999, 9, 1371-1374.	1.0	27
467	Synthesis of 8-oxa analogues of norcocaine endowed with interesting cocaine-like activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1999, 9, 1831-1836.	1.0	14
468	MCDOCK: a Monte Carlo simulation approach to the molecular docking problem. , 1999, 13, 435-451.		140

#	ARTICLE	IF	CITATIONS
469	The Transition from a Pharmacophore-Guided Approach to a Receptor-Guided Approach in the Design of Potent Protein Kinase C Ligands. , 1999, 82, 251-261.		40
470	Probing the Binding of Indolactam-V to Protein Kinase C through Site-Directed Mutagenesis and Computational Docking Simulations. Journal of Medicinal Chemistry, 1999, 42, 3436-3446.	2.9	30
471	Recognition and interaction of small rings with the ricin A-chain binding site. , 1998, 31, 33-41.		31
472	Synthesis and anticholinesterase activity of huperzine A analogues containing phenol and catechol replacements for the pyridone ring. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 1413-1418.	1.0	35
473	Conformationally constrained analogues of diacylglycerol (DAG). 14.1 Dissection of the roles of the sn-1 and sn-2 carbonyls in DAG mimetics by isopharma cophore replacement. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 1757-1762.	1.0	16
474	Conformationally constrained analogues of diacylglycerol (DAG). 15.1 The indispensable role of the sn-1 and sn-2 carbonyls in the binding of DAG-lactones to protein kinase C (PK-C). Bioorganic and Medicinal Chemistry Letters, 1998, 8, 3403-3408.	1.0	20
475	Structure-based design and synthesis of small molecule proteinâ€“tyrosine phosphatase 1B inhibitors 1A preliminary account of this work have been reported: Burke, T. R., Jr.; Yao, Z. J.; Ye, B.; Wang, S.; Zhang, Z. Y. Structure-based design of proteinâ€“tyrosine phosphatase inhibitors. Presented at the 213th National ACS Meeting, San Francisco, CA, April 13â€“17, 1997; MEDI-313. 1. Bioorganic and Medicinal Chemistry, 1998, 6, 1799-1810.	1.4	53
476	Structure-Based Design of a New Class of Protein Kinase C Modulators. Journal of the American Chemical Society, 1998, 120, 6629-6630.	6.6	40
477	Self-Guided Molecular Dynamics Simulation for Efficient Conformational Search. Journal of Physical Chemistry B, 1998, 102, 7238-7250.	1.2	108
478	Synthesis and Biology of the Conformationally Restricted ACPD Analogue, 2-Aminobicyclo[2.1.1]hexane-2,5-dicarboxylic Acid-I, a Potent mGluR Agonist. Journal of Medicinal Chemistry, 1998, 41, 1641-1650.	2.9	66
479	Characterization of C-10 Substituted Analogues of Huperzine A as Inhibitors of Cholinesterases. Advances in Behavioral Biology, 1998, , 601-605.	0.2	0
480	Nonphosphorylated Peptide Ligands for the Grb2 Src Homology 2 Domain. Journal of Biological Chemistry, 1997, 272, 29046-29052.	1.6	98
481	Hydrazide-Containing Inhibitors of HIV-1 Integraseâ€“. Journal of Medicinal Chemistry, 1997, 40, 937-941.	2.9	106
482	Modeling, Chemistry, and Biology of the Benzolactam Analogues of Indolactam V (ILV). 2. Identification of the Binding Site of the Benzolactams in the CRD2 Activator-Binding Domain of PKC δ and Discovery of an ILV Analogue of Improved Isozyme Selectivity. Journal of Medicinal Chemistry, 1997, 40, 1316-1326.	2.9	75
483	Coumarin-Based Inhibitors of HIV Integrase. Journal of Medicinal Chemistry, 1997, 40, 242-249.	2.9	280
484	Discovery of HIV-1 Integrase Inhibitors by Pharmacophore Searchingâ€“. Journal of Medicinal Chemistry, 1997, 40, 930-936.	2.9	126
485	Depsides and Depsidones as Inhibitors of HIV-1 Integrase:â€“Discovery of Novel Inhibitors through 3D Database Searchingâ€“. Journal of Medicinal Chemistry, 1997, 40, 942-951.	2.9	214
486	Synthesis, molecular modeling, and biology of the 1-benzyl derivative of APDC-an apparent mGluR6 selective ligand. Bioorganic and Medicinal Chemistry Letters, 1997, 7, 601-606.	1.0	55

#	ARTICLE	IF	CITATIONS
487	Antiretroviral Agents as Inhibitors of both Human Immunodeficiency Virus Type 1 Integrase and Protease. <i>Journal of Medicinal Chemistry</i> , 1996, 39, 2472-2481.	2.9	155
488	Discovery of Novel, Non-Peptide HIV-1 Protease Inhibitors by Pharmacophore Searching. <i>Journal of Medicinal Chemistry</i> , 1996, 39, 2047-2054.	2.9	133
489	Identification of a More Potent Analogue of the Naturally Occurring Alkaloid Huperzine A. Predictive Molecular Modeling of Its Interaction with AChE. <i>Journal of the American Chemical Society</i> , 1996, 118, 11357-11362.	6.6	99
490	Molecular Modeling and Site-Directed Mutagenesis Studies of a Phorbol Ester-Binding Site in Protein Kinase C. <i>Journal of Medicinal Chemistry</i> , 1996, 39, 2541-2553.	2.9	46
491	Conformationally Constrained Analogues of Diacylglycerol. 10. Ultrapotent Protein Kinase C Ligands Based on a Racemic 5-Disubstituted Tetrahydro-2-furanone Template. <i>Journal of Medicinal Chemistry</i> , 1996, 39, 19-28.	2.9	44
492	Molecular Modeling in the Discovery of Drug Leads. <i>Journal of Chemical Information and Computer Sciences</i> , 1996, 36, 726-730.	2.8	12
493	Conformationally Constrained Analogues of Diacylglycerol. 12.1 Ultrapotent Protein Kinase C Ligands Based on a Chiral 4,4-Disubstituted Heptono-1,4-lactone Template. <i>Journal of Medicinal Chemistry</i> , 1996, 39, 36-45.	2.9	35
494	Conformationally Constrained Analogues of Diacylglycerol. 11.1 Ultrapotent Protein Kinase C Ligands Based on a Chiral 5-Disubstituted Tetrahydro-2-furanone Template. <i>Journal of Medicinal Chemistry</i> , 1996, 39, 29-35.	2.9	37
495	Synthesis and biology of the rigidified glutamate analogue, trans-2-carboxyazetidino-3-acetic acid (t-CAA). <i>Bioorganic and Medicinal Chemistry Letters</i> , 1996, 6, 2559-2564.	1.0	27
496	Conformational changes of small molecules binding to proteins. <i>Bioorganic and Medicinal Chemistry</i> , 1995, 3, 411-428.	1.4	230
497	Residues in the Second Cysteine-rich Region of Protein Kinase C \hat{r} Relevant to Phorbol Ester Binding as Revealed by Site-directed Mutagenesis. <i>Journal of Biological Chemistry</i> , 1995, 270, 21852-21859.	1.6	143
498	Resiniferatoxin \hat{r} Amide and Analogues as Ligands for Protein Kinase C and Vanilloid Receptors and Determination of Their Biological Activities as Vanilloids. <i>Journal of Neurochemistry</i> , 1995, 65, 301-308.	2.1	24
499	Conformationally constrained analogues of diacylglycerol. 6. Changes in PK-C binding affinity for 3-O-acyl-2-deoxy-L-ribofuranolactones bearing different acyl chains. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1994, 4, 355-360.	1.0	11
500	Prediction of geometries and interaction energies of complexes formed by small molecules using semiempirical and ab initio methods. <i>Computational and Theoretical Chemistry</i> , 1994, 309, 279-294.	1.5	13
501	Computer Automated log P Calculations Based on an Extended Group Contribution Approach. <i>Journal of Chemical Information and Computer Sciences</i> , 1994, 34, 752-781.	2.8	279
502	The Discovery of Novel, Structurally Diverse Protein Kinase C Agonists through Computer 3D-Database Pharmacophore Search. <i>Molecular Modeling Studies. Journal of Medicinal Chemistry</i> , 1994, 37, 4479-4489.	2.9	79
503	Graph Theory and Group Contributions in the Estimation of Boiling Points. <i>Journal of Chemical Information and Computer Sciences</i> , 1994, 34, 1242-1250.	2.8	20
504	Protein Kinase C. Modeling of the Binding Site and Prediction of Binding Constants. [Erratum to document cited in CA121:29778]. <i>Journal of Medicinal Chemistry</i> , 1994, 37, 4422-4422.	2.9	0

#	ARTICLE	IF	CITATIONS
505	National Cancer Institute Drug Information System 3D Database. Journal of Chemical Information and Computer Sciences, 1994, 34, 1219-1224.	2.8	141
506	Protein Kinase C. Modeling of the Binding Site and Prediction of Binding Constants. Journal of Medicinal Chemistry, 1994, 37, 1326-1338.	2.9	40
507	Applications of computers to toxicological research. Chemical Research in Toxicology, 1993, 6, 748-753.	1.7	14
508	Anti- Mycobacterium avium Activity of Quinolones: In Vitro Activities. Antimicrobial Agents and Chemotherapy, 1993, 37, 2766-2766.	1.4	0
509	Estimation of aqueous solubility of organic molecules by the group contribution approach. Application to the study of biodegradation. Journal of Chemical Information and Modeling, 1992, 32, 474-482.	2.5	147
510	A computer automated structure evaluation (CASE) approach to calculation of partition coefficient. Journal of Computational Chemistry, 1991, 12, 1025-1032.	1.5	78
511	Basic Principles and Practices of Computer-Aided Drug Design. , 0, , 259-278.		0